Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intranasal Modified Temozolomide (Center Trials & Treatment Europe)
- Development stage
- Unknown
- Lead developer
- Center Trials & Treatment Europe
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Intranasal Modified Temozolomide (IM-TMZ) is an investigational formulation of the standard chemotherapy agent temozolomide, specifically designed for direct administration to the brain via the intranasal route. Developed by Center Trials & Treatment Europe, this approach aims to bypass the blood-brain barrier (BBB) by utilizing the olfactory and trigeminal nerve pathways, thereby delivering therapeutic doses directly to the neoplastic process in the central nervous system while potentially reducing systemic toxicity and side effects such as myelosuppression. Temozolomide is a prodrug that undergoes spontaneous hydrolysis at physiological pH to its active metabolite, MTIC, which acts as a DNA alkylating agent. It methylates DNA primarily at the O6 and N7 positions of guanine, leading to DNA damage and subsequent apoptosis in tumor cells. IM-TMZ is currently being evaluated in Phase 1 clinical trials for the treatment of high-grade gliomas, including glioblastoma, gliosarcoma, and Grade 4 astrocytoma.
- Other names
- Intranasal TemozolomideModified Temozolomide
02
Targets
DNA
Beyond the preview
Go deeper on Intranasal Modified Temozolomide (Center Trials & Treatment Europe).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intranasal Modified Temozolomide (Center Trials & Treatment Europe).